Early-Stage Investors Hedge Their Bets with Medical Devices

GEN -- Despite the biotech industry losing approximately $100 billion since the field’s inception in the 1970s, the days of investing in biotechs are not dead. Biotechs are important sources of healthcare innovation. They have filled the gap created by the slowdown in the R&D pipeline of big pharmaceutical and medical device companies over the years. Additionally, biotech companies are responsible for creating a large number of drug candidates.

MORE ON THIS TOPIC